Project Grant HT94252410620

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting a Phase 2 multi-center clinical trial of a novel CD5 CAR T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The $1,124,607 award, with a performance period of Jul 1, 2025 to Jun 30, 2027, aims to validate the safety and efficacy of this innovative cellular therapy that is engineered to selectively target...

This $1,340,987 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel "CAR-Enhancer" platform to improve the effector function and persistence of CAR T-cells. The project's key objectives are to: 1) Optimize dosing and timing for CAR-Enhancer administration in a Phase I clinical trial, 2) Establish a scalable manufacturing process, and 3) Assess the...

This $400,000 Project Grant was awarded on August 4, 2025 by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by Lifengine Animal Health Laboratories Incorporated to develop chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion. Specifically, the project aims to engineer CAR-T cells to overexpress the C-MYB transcription factor, which has been shown in mice to enhance anti-tumor...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...

The National Cancer Institute (NCI), under the Federal grant program "Cancer Treatment Research" (CFDA 93.395), awarded Persistence Therapeutics, Inc. $629,370 on September 22, 2025 to support the development of a novel CAR T cell therapy approach called "SynthNode." This implantable device mimics the function of a synthetic lymph node, producing potent antigen-specific cells that persist for improved patient outcomes. The project aims to address key challenges in current CAR...

The National Cancer Institute (NCI) awarded a $1,125,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Kure Ai Inc. to develop an "Ultra-Fast Manufactured CAR-T Therapy" with improved efficacy and safety compared to current CAR-T cell therapies. The project aims to 1) validate an automated, closed-system manufacturing process for this rapid CAR-T product through a Phase 1b clinical trial, and 2) extend the safety and efficacy data in a defined...

This federal Project Grant award of $470,759 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to develop a novel CAR T-cell therapy for patients with hepatocellular carcinoma. The goal is to prevent CAR T-cell exhaustion, a key barrier to effective solid tumor treatment, by overexpressing the JMJD6 transcription factor using a precise, RNA-level control system called the "PA-Regulator" platform. The research, conducted...

This Project Grant award, funded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development and clinical evaluation of next-generation CAR-NK cell therapies targeting CD5-positive T-cell malignancies. The $1,847,485 award to the University of Texas MD Anderson Cancer Center aims to advance a novel CAR-NK cell product, termed IC9/CAR5-28Z/IL-15 NK cells, that leverages key advantages of NK cells over traditional CAR-T cell therapies. The project seeks to...

This $399,625 project grant was awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to Cellchorus Inc., a Houston-based company specializing in advanced cell analysis technologies. The project aims to develop a scalable, high-throughput single-cell analysis platform called TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) to profile post-infusion chimeric antigen receptor (CAR) T cells from patients with relapsed/refractory large B cell...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...